Noel Byrne

Associate Principal Scientist and Lead, Expression Group, Target Protein Design
Merck
Noel Byrne
Integral membrane proteins represent more than 60% of current drug targets. Despite the clinical significance, therapeutic agents that target membrane proteins have been difficult to develop. Poor expression in recombinant systems is the most critical challenge to producing functional integral membrane proteins for antibody discovery, structural and functional studies. The results from our on-going exploration of different technologies for efficient mammalian expression of several GPCRs and Ion Channels through stable cell-line generation and transient expression (DNA and BacMam) will be presented.

Sessions

No data was found